Anthrone Or Anthraquinone Patents (Class 544/156)
-
Patent number: 11255761Abstract: According to the invention there is provided a compound of Formula (I) in which: A is a C2-8 alkylene group; R1, R2, R3, and R4 are independently selected from hydrogen, C1-4 alkyl, C2-4 dihydroxyalkyl in which the carbon atom attached to the nitrogen atom does not carry a hydroxyl group and no carbon atom is substituted by two hydroxyl groups, or R2 and R3 together form a C2-6 alkylene group which with the nitrogen atom to which R2 and R3 are attached forms a heterocyclic ring; X1, X2 and X3 are independently selected from hydrogen, hydroxyl, NR1-A-NR2R3R4+(Zm?)1/m, for halogeno amino, C1-4 alkoxy or C2-8 alkanoyloxy; and (Zm?)1/m is an anion of charge m; or a derivative in which the group NR1 is quaternarized.Type: GrantFiled: June 5, 2015Date of Patent: February 22, 2022Assignee: Biostatus LimitedInventors: Paul James Smith, Rachel J. Errington, Laurence Hylton Patterson
-
Patent number: 9260408Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.Type: GrantFiled: September 13, 2012Date of Patent: February 16, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Aebi, Kurt Amrein, Benoit Hornsperger, Henner Knust, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Alexander V. Mayweg, Peter Mohr, Xuefei Tan, Mingwei Zhou
-
Patent number: 8530465Abstract: The invention provides a series of novel 1,2-disubstituted amido-anthraquinone derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with therapeutically effective amount are prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.Type: GrantFiled: August 1, 2012Date of Patent: September 10, 2013Assignee: National Defense Medical CenterInventors: Hsu-Shan Huang, Chia-Chung Lee
-
Patent number: 8445492Abstract: A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH2)nX, a straight (CH2)n alkyl group, a (CH2)n alkoxyl group, a branched (CH2)n alkyl group, a C3˜C12 naphthenic group, and a C3˜C12 cyclic alkoxyl group, wherein 1?n?12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C1˜C8 alkyl group with a double-bond, a C1˜C8 alkoxyl group with a double-bond, a branched C1˜C8 alkyl group with a double-bond and a C3˜C8 naphthenic group with a double-bond, and iv) a fourth substituent of a C5˜C12 heterocyclic group.Type: GrantFiled: March 29, 2010Date of Patent: May 21, 2013Assignee: National Defense Medical CenterInventor: Hsu-Shan Huang
-
Patent number: 8304415Abstract: A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.Type: GrantFiled: February 25, 2010Date of Patent: November 6, 2012Assignee: National Defense Medical CenterInventors: Hsu-Shan Huang, Chia-Chung Lee
-
Patent number: 8124799Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.Type: GrantFiled: April 20, 2009Date of Patent: February 28, 2012Assignee: Reata Pharmaceuticals, Inc.Inventors: Eric Anderson, Xin Jiang, Melean Visnick
-
Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof
Publication number: 20110207739Abstract: A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.Type: ApplicationFiled: February 25, 2010Publication date: August 25, 2011Inventor: Hsu-Shan HUANG -
Patent number: 7767719Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.Type: GrantFiled: April 9, 2007Date of Patent: August 3, 2010Assignee: SunTen Phytotech Co., Ltd.Inventors: Du-Shieng Chien, Yi-Wen Chu, Wu-Chang Chuang, Ming-Chung Lee
-
Publication number: 20090156807Abstract: Compounds for utilization as anti-tumor agents against cancer and certain inflammatory and arthritic conditions designed with multiple active sites to cause inhibition and cell death synthesized from the starting compound 1,4,5,8-tetrachloroanthraquinone. Included are anti-tumor compounds of the class 1,4,5,8-tetrakis-alkylaminoalkyl, 1,4,5,8-tetrakis-hydroxyalkylaminoalkyl, 1,4,5,8-tetrakis-chloroethylamino, 1,2-bischloroethylamino-1,4,5,8-tetrakis-aminoethylamino derivatives of Anthraquinone. Also includes mixtures of groupings such as 1-aminoalkylamino-4,5,8-tris-(1,2-dimethyl)aminoalkylamino anthraquinone, 1,2-dichloroethyl 1-aminoalkyl amino-4,5,8-tris-aminoethylamino anthraquinone, bis-1,4aminoalkylamino bis-5,8-alkylaminoanthraquinone, 1,4-bis-chloroalkylamino-5,8-bisaminoalkylamino anthraquinone and others.Type: ApplicationFiled: October 16, 2008Publication date: June 18, 2009Inventor: D. Richard Ishmael
-
Publication number: 20080261985Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: ApplicationFiled: November 16, 2007Publication date: October 23, 2008Inventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby
-
Patent number: 7034110Abstract: A method for obtaining compounds having selected properties for a particular application by forming base modules having at least two structural diversity elements from the reaction of a first compound having at least one structural diversity element and a first reactive group, with a second compound having at least one structural diversity element and a second reactive group, wherein the first and second groups combine by an addition reaction; producing a first array of molecules by varying at least one of the structural diversity elements of the compounds when producing the base modules; and screening the array to determine a first suitable compound for the particular application. The base modules are preferably formed form oxazolone- and aminimide-derived compounds.Type: GrantFiled: January 23, 2004Date of Patent: April 25, 2006Assignee: ArQule, Inc.Inventor: Joseph C. Hogan, Jr.
-
Publication number: 20040175314Abstract: A method of scavenging oxygen in an atmosphere or liquid comprising the steps of: (i) treating an anthraquinone compound according to the formula: (I) wherein X1-X4 and R1-R4 are as defined in the claims, with predetermined conditions so as to reduce the anthraquinone compound to a reduced form oxidizable by oxygen; and ii) exposing the atmosphere or liquid to said compound; such that at least a portion of teh oxygen in teh atmosphere or liquid is removed through oxidation of the reduced form of the anthraquinone compound, and wherein steps i) and ii) may be carried out in either order.Type: ApplicationFiled: May 12, 2004Publication date: September 9, 2004Inventors: Mark Andrew Horsham, Andrew David Scully, James Keith Gerard Murphy
-
Publication number: 20040077854Abstract: The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.Type: ApplicationFiled: October 10, 2003Publication date: April 22, 2004Inventors: Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Patent number: 6653307Abstract: The present invention provides compounds of formula I which are useful as antiviral agents, in particular, as agents against viruses of the herpes family.Type: GrantFiled: June 5, 2001Date of Patent: November 25, 2003Assignee: Pharmacia & Upjohn CompanyInventor: Mark E. Schnute
-
Patent number: 6566520Abstract: A method for the preparation and purification of compounds using a novel support, a tetrabenzo [a, c, g, i]-fluorene group (Tbf) comprising reacting a building block (A) containing a Tbf group (Tbf-A), with a second building block (B), to afford an intermediate compound (Tbg-A-B) followed by purifying the intermediate compound by adsorption on a carbon support, removing the intermediate compound from the support with a solvent and repeating the previous reactions using the required number of building blocks to synthesize the compounds followed by removal of the Tbf group to afford the desired compounds.Type: GrantFiled: April 14, 1999Date of Patent: May 20, 2003Assignee: Warner-Lambert CompanyInventors: Sheila Helen DeWitt, Robert Ramage, Alasdair Arthur MacDonald
-
Patent number: 5436243Abstract: Potentiating agents inhibit the development of multidrug resistance, reduce drug-resistance in drug-resistant tumors, or sensitize tumors to antineoplastic drugs, thereby potentiating the effect of antineoplastic agents. The potentiating agents are aminoanthraquinones, preferably 1,4-bis(N-substituted) amino anthraquinones, and pharmaceutically acceptable salts thereof.Type: GrantFiled: November 17, 1993Date of Patent: July 25, 1995Assignees: Research Triangle Institute Duke University, Pharmaceuticals CorporationInventors: Clifford W. Sachs, Robert L. Fine, Lawrence M Ballas, R. Ivy Carroll, Robert Bell
-
Patent number: 5174913Abstract: A corrosion inhibitor with excellent film forming and film persistency characteristics may be produced by first reacting in a condensation reaction a polybasic acid with a polyalcohol to form a partial ester. The partial ester is reacted with imidazoline and/or fatty diamines to salt the ester. If warranted, the salted partial ester may be reacted with a metal hydroxide, a metal oxide, and/or ammonia to further salt the ester. Surfactants may be added to tailor the inhibitor formulation to meet the specific needs of the user (i.e., the corrosion inhibitor may be formulated to produce an oil-soluble, highly water-dispersible corrosion inhibitor or an oil-dispersible, water-soluble corrosion inhibitor). Suitable carrier solvents may be employed where needed to effectively disperse the corrosion inhibitor formulation.Type: GrantFiled: September 20, 1991Date of Patent: December 29, 1992Assignee: Westvaco CorporationInventors: John A. Alford, Paul G. Boyd, Eugene R. Fischer
-
Patent number: 4950756Abstract: 1-Nitroanthraquinone-2-carboxylic acid of the formula I ##STR1## is prepared by treating novel 2-substituted 1-nitroanthraquinones of the general formula II ##STR2## where R is --CH.dbd.CH--R.sup.1 or --CH.sub.2 --CHO, where R.sup.1 is C.sub.1 -C.sub.5 -dialkylamino or a cyclic 5- or 6-membered amine which may contain further hetero atoms, with oxidizing agents free of heavy metal.Type: GrantFiled: October 30, 1989Date of Patent: August 21, 1990Assignee: BASF AktiengesellschaftInventors: Jochem Henkelmann, Helmut Hoch, Thomas-Michael Kahl, Gerhard Kilpper, Walter Maier
-
Patent number: 4894451Abstract: The disclosure describes unsymmetrical 1,4-bis-(aminoalkylamino)-anthracene-9,10-diones useful in the treatment of neoplasms. Also described is a process of preparing same starting from 1,4-dimethoxyanthracene-9,10-dione which is reacted with an aminoalkylamine. The reaction product is treated with a dialkylaminoethylamine or a N-heteroethylamine to give the unsymmetrical compound.Type: GrantFiled: July 19, 1988Date of Patent: January 16, 1990Assignee: The University of VermontInventors: A. Paul Krapcho, Miles P. Hacker, John J. Landi, Jr., J. J. McCormack, Kenneth J. Shaw
-
Patent number: 4782092Abstract: Chemical compounds are provided that are novel 5,8-dichloro-4-hydroxy-1-[(aminoalkyl)amino]-9,10-anthracenediones (I), as well as a method for their production, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds in dosage form. Compounds of the invention have pharmacological properties and are useful antimicrobial agents and antitumor agents.Type: GrantFiled: July 3, 1986Date of Patent: November 1, 1988Assignee: Mid-America Cancer CenterInventors: Robert K. Zee-Cheng, Chia C. Cheng
-
Patent number: 4540519Abstract: This disclosure describes symmetrical 1,4-bis-(substituted-amino)-5,8-hydroxyanthraquinones useful as chelating agents and for inducing regression and/or palliation of cancer diseases in mammals.Type: GrantFiled: April 9, 1984Date of Patent: September 10, 1985Assignee: American Cyanamid CompanyInventors: Keith C. Murdock, Frederick E. Durr
-
Patent number: 4517183Abstract: The present invention provides pharmaceutical compositions containing N-substituted aziridine-2-carboxylic acid derivatives of the general formula: ##STR1## wherein X is a carboxyl, a cyano, an alkoxycarbonyl or an optionally substituted carbamoyl radical, R is a hydrogen atom, an aliphatic hydrocarbon radical which is saturated or can contain one or more unsaturations and can be substituted one or more times by halogen, alkoxy, hydroxyl, dialkylamino, dialkylaminoxy, cycloalkylamino, acylamino, acyl, nitro, alkylthio, alkylsulphinyl, alkylsulphonyl, cyano, carboxyl, alkoxycarbonyl or carbamoyl or by cycloalkyl or cycloalkenyl radicals optionally carrying alkyl, alkoxy or alkoxycarbonyl radicals, optionally interrupted by hetero atoms and optionally bridged, or by an aryl, hetaryl, aryloxy, arylthio, acyloxy, alkoxycarbonylamino or isothioureido radical, or R is a cycloalkyl or cycloalkenyl radical optionally substituted by alkyl, alkoxy or oxo groups, optionally interrupted by hetero atoms and optionally briType: GrantFiled: May 17, 1983Date of Patent: May 14, 1985Assignee: Boehringer Mannheim GmbHInventors: Elmar Bosies, Wolfgang Kampe, Max Thiel, Uwe Bicker, Dietmar Boerner
-
Patent number: 4374984Abstract: Compounds of the formula ##STR1## wherein the substituents A, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, n and m are defined hereinbeloware effective photoinitiators, especially for the photopolymerization of ethylenically unsaturated compounds and for the curing of printing inks.Type: GrantFiled: March 4, 1981Date of Patent: February 22, 1983Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Jurgen Eichler, Claus Herz, Karl-Heinz Neisius, Gregor Wehner